Unmesh Lal

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new trials. This research service will help participants plan their production pipeline and be well prepared to tackle the dynamic market situation and… Mehr anzeigen

In this research deliverable, Frost & Sullivan’s analyst team offers a bold perspective on the post-pandemic growth opportunities for the global CRO market. With the increased threat of COVID-19 and world-wide lockdowns in effect, the contract research organization (CROs) market is seeing interruptions in ongoing clinical trials and delays of new trials. This research service will help participants plan their production pipeline and be well prepared to tackle the dynamic market situation and the post-COVID-19 impact. This short report covers the Global Contract Research Organization Market (CRO) insights, with forecast for the total CRO market, including drug discovery and preclinical markets, with 2019 as the base year and 2020–2024 as the forecast period. Market revenue is measured in US dollars. It presents an overview and analysis of the global clinical trials and research outsourcing (CRO) market. It provides global, post-pandemic revenue forecasts for CROs. Further, qualitative information will be provided on support services, such as central laboratory services, bioanalytics, and data management. The report identifies strong CRO opportunities, with the evolving digitized ecosystem of the clinical trials due to COVID-19. The two key market trends identified are increased adoption of hybrid clinical trials and remote patient monitoring. Weniger anzeigen

The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compound annual growth rate (CAGR) of ~5.2% from 2020. While Europe is the highest contributor to the total market, Asia-Pacific (APAC) is expected to… Mehr anzeigen

The biobanking ecosystem is witnessing significant transformation. Emergence of one-stop shops and virtual biobanks, rise in services offered to sustain and improve positioning, and precision medicine are characterizing this transformative environment. The biobanking market is expected to reach a size of ~$71.2 billion by 2026, registering a compound annual growth rate (CAGR) of ~5.2% from 2020. While Europe is the highest contributor to the total market, Asia-Pacific (APAC) is expected to witness the highest growth during the forecast period (2020 to 2026) of this research. This market will be driven further by innovation in targeted therapeutic applications, high sample utilization of tissue/stem cells, and the increasing demand for bio-data for enabling patient stratification. Significant growth opportunities for biobanks are in the areas of companion diagnostics (CDx) co-development, large-scale genome sequencing projects, immuno-oncology clinical development, digital pathology services, and real-world evidence (RWE) studies.

The shifting industry paradigm towards commercial partnerships with pharmaceutical and biotech companies, contract research organizations (CROs), and contract development and manufacturing organizations (CDMOs), as well as diagnostics and digital solution providers is expected to further boost market growth. Biobanks are partnering with end-users for customized research-based engagements as niche providers of samples and services and as data owners. However, they need to better understand the changing end-user needs and transition to innovative value-based data pricing and hybrid models for ensuring operational sustainability in the future. Collaborations with commercial partners by fulfilling key selection criteria and engaging with well-defined models are a critical requirement for biobanks to retain market share. Weniger anzeigen

With this research service, Frost & Sullivan’s Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, recombinant proteins, vaccines, and regenerative medicine. The forecast for the global biologics market till 2024 reveals interesting trend and… Mehr anzeigen

With this research service, Frost & Sullivan’s Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, recombinant proteins, vaccines, and regenerative medicine. The forecast for the global biologics market till 2024 reveals interesting trend and paradigm shifts that are set to take place in the industry. Importantly, the study also identifies actionable growth opportunities for industry participants to profit upon.

This research service identifies the largest revenue-generating segments and key therapeutic areas for the global biologics industry. Accelerated regulatory approvals for biologic products and the emergence of next-generation technologies are highlighted, in addition to their influence on market trends during the forecast period. The study highlights the dynamics of the biologics industry and the sub-segments of the biologics market. Growth opportunities in antibody-drug conjugate (ADC), RNA therapy, and gene therapy platforms are also explored. Further, the study discusses the impact (such as the accelerated development of vaccines) of the COVID-19 pandemic on the biologics industry and the market. Current challenges facing the biologics industry such as the sluggish growth rate of vaccines, and recombinant proteins are discussed. Most importantly, this research service discusses possible future market trends such as the accelerated development of mRNA-based vaccines and the increasing importance of specialty bio-CDMOs for the development and commercialization of regenerative medicine. Based on the market trends and revenue forecasts, Frost & Sullivan’s group of analysts highlight key growth opportunities in ADC, RNA, and gene therapy platforms. Weniger anzeigen

Every year, the team of futurists, analysts, and consultants in Frost & Sullivan's Transformational Healthcare Group comes together to render a comprehensive analysis to predict the themes, technologies, and global forces that will define the next 12 to 18 months (future) for the healthcare industry. In light of the lessons learned from the COVID-19 pandemic and the changing economic and business scenario, Frost & Sullivan has re-visited predictions and identified the top growth opportunities… Mehr anzeigen

Every year, the team of futurists, analysts, and consultants in Frost & Sullivan's Transformational Healthcare Group comes together to render a comprehensive analysis to predict the themes, technologies, and global forces that will define the next 12 to 18 months (future) for the healthcare industry. In light of the lessons learned from the COVID-19 pandemic and the changing economic and business scenario, Frost & Sullivan has re-visited predictions and identified the top growth opportunities for companies to survive the remainder of 2020. Among the considerations:

• Disrupted clinical trials and the subsequent delay in drug launches will pave the way for fully virtual trials, and hybridization of patient recruitment, retention, and monitoring will become pervasive.
• An increase in point-of-care testing for infectious diseases is inevitable. With the looming change in service models, alternate testing sites such as pharmacies will become permanent ecosystem participants.
• The supply of ventilators and critical care monitoring devices across regions has been uneven during the pandemic, but embedded analytics systems will revive the mature monitoring devices segment post-pandemic.
• A resumption in imaging for the backlog of elective procedures in Q3 and Q4 2020 will be met by teleradiology and artificial intelligence-based solutions gaining from new investments. Scale-up in capacity, flexible payment options, and redistribution of the workload to manage deferrals will determine partnerships.
• A tenfold increase in virtual consultations by healthcare providers is laying the foundation for the new normal. Reimbursement, physician training, and platform scalability will be key to recalibrate care delivery.

Amid the uncertainty, leading healthcare players are adopting risk-mitigation measures and reprioritizing opportunities to recover from the pandemic and rebuild shareholder confidence. Weniger anzeigen

The global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies are also striving to customize and expand the application of existing technologies into emerging areas, such as Femtech and emerging geographies… Mehr anzeigen

The global life science industry is in a state of flux. While the recent years have seen the advent of multiple novel technologies, such as in-vitro diagnostics (IVD), CRISPR-Cas9, virtual clinical trials, and liquid biopsy, the industry stands at a crossroad with challenges in scaling-up and commercializing such technologies. In addition, companies are also striving to customize and expand the application of existing technologies into emerging areas, such as Femtech and emerging geographies such as Asia-Pacific.
As the life sciences industry attempts to catch up with the digital revolution, the movement towards customer centricity is challenging traditional stakeholders such as Big Pharma, diagnostic companies, and site management organizations (SMOs) to improve their business strategy and embrace mHealth solutions. Companies in the life sciences industry are increasingly adopting a digital-first mindset in the wake of rapidly declining returns on research and development (R&D) and the complexity of financial precision medicine equation catering to select and small population groups.
The future will bring more digitally integrated solutions based on R&D advancements; this will influence how clinical trials are designed and how new products are commercialized. While the need for value-based-care grows along with strained profitability, Big Pharma needs to decentralize and outsource manufacturing of novel cell and gene therapies to contract development and manufacturing organization (CDMOs).
The convergence of pharmaceuticals, clinical laboratory testing services, and companion diagnostics, which has been enabled by digital connectivity, is driving regulatory and commercial changes in the global life sciences industry. Mergers and acquisitions (M&As) play a very significant role in achieving these industry changes. Weniger anzeigen

PCR continues to be the gold standard for nucleic acid amplification by combining accuracy and efficacy that users across areas such as research, pharma & biotech, diagnostics as well as applied sciences depend upon. Such widespread usage continues to drive the industry, even protecting it to some extent from overall economic/market fluctuations. However, as the industry matures, companies are innovating across instrument technology, reagents, and software solutions in order to maintain a… Mehr anzeigen

PCR continues to be the gold standard for nucleic acid amplification by combining accuracy and efficacy that users across areas such as research, pharma & biotech, diagnostics as well as applied sciences depend upon. Such widespread usage continues to drive the industry, even protecting it to some extent from overall economic/market fluctuations. However, as the industry matures, companies are innovating across instrument technology, reagents, and software solutions in order to maintain a competitive edge. As leading markets such as the United States and Europe face cost pressures, companies are offering solutions around multiplexing and high throughput devices. Reagent manufacturers are focused on products that allow for high speed, efficacy, lower processing cost, reliable repeatability/consistency, sensitivity, and multiplexing capabilities. They are increasingly focusing on novel applications in oncology, infectious diseases, aging related diseases, as well as applied sciences areas such as forensics, nutrition sciences, agriculture, and veterinary sciences to drive growth. Weniger anzeigen

Globally, 2019 will be a year of value-based care, as ‘outcome-based care’ focus will globalize. This will trigger the maturation of risk-sharing in solution contracting between providers and drug/device OEMs, driving business value for providers. Access to affordable and quality care will be key political agendas for the upcoming 2019 elections in emerging markets such as Asia, Africa, and Central and Eastern European countries. Future drugs and devices R&D investments will be more targeted to… Mehr anzeigen

Globally, 2019 will be a year of value-based care, as ‘outcome-based care’ focus will globalize. This will trigger the maturation of risk-sharing in solution contracting between providers and drug/device OEMs, driving business value for providers. Access to affordable and quality care will be key political agendas for the upcoming 2019 elections in emerging markets such as Asia, Africa, and Central and Eastern European countries. Future drugs and devices R&D investments will be more targeted to meet the unique needs of emerging markets.

As the lines between retail, IT, and healthcare markets continue to blur, digital marketplace providers such as Amazon will dominate the home health space, but will find it difficult to compete in the traditional B2B hospital/providers space dominated by established participants. Non-traditional participants such as Amazon, Ali Health, Microsoft, and IBM with digital technologies will provide the required impetus to public health systems to ensure accessibility and affordability of care. During 2019, digital health will start to come of age—favorable reimbursement policies toward clinically relevant digital health applications will expand care delivery models beyond physical medicine to include behavioral health, digital wellness therapies, dentistry, nutrition, and prescription management. Weniger anzeigen

Rapid technological turnaround has become a norm in the life science and in-vitro diagnostic industry. Extrinsic factors such as lack of skilled labor to operate the instrumentation as well as functional factors like demand for very high precision and reproducibility of results are driving this technological evolution. As the instrument efficiency goes on increasing, the aftermarket for instruments will gain four to five times the value of the original equipment manufacturing market in the next… Mehr anzeigen

Rapid technological turnaround has become a norm in the life science and in-vitro diagnostic industry. Extrinsic factors such as lack of skilled labor to operate the instrumentation as well as functional factors like demand for very high precision and reproducibility of results are driving this technological evolution. As the instrument efficiency goes on increasing, the aftermarket for instruments will gain four to five times the value of the original equipment manufacturing market in the next ten years.

Even though this space is dominated by a handful of very large participants like Thermo Fisher and Perkin Elmer, there has been measurable growth of small- to medium-sized participants in the last five years. A shift in competitive factors from delivering end-to-end product portfolio to providing high-value super-specialized innovation is witnessed. Although there is an evident overlap in the product offerings to research labs and commercial reference labs, a remarkable difference in the purchasing patterns and product lifecycle management has been observed. This research study covers the shifting dynamics between end users and an accelerating trend in consolidation, influencing the purchasing trends. The study also captures the additional play between different value chain participants like the OEMs and CMOs and rising trend in outsourcing. While there has been exponential growth in demand for diagnostic services, there is a constant pressure to do so under budget and skill constraints. This has led to rise of new technologies that are not only pushing the envelope on sensitive, rapid, and accurate testing but are also affordable in terms of reducing the cost of total treatment cycle. This study identifies some of the key technology trends empowered by innovation in functional consumables and growth opportunities, which are set to drive the market in the next five years. Weniger anzeigen

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global biologics Contract Development and Manufacturing Organization (CDMO) landscape with an emphasis on the key trends and growth opportunities across the… Mehr anzeigen

The global pharmaceutical industry is evolving with the rising need for novel therapies in the changing disease landscape. As a result of rising prevalence of chronic infectious diseases as well as growing cancer incidence, market needs are shifting from traditional small molecules to large molecules. This study presents an overview of the global biologics Contract Development and Manufacturing Organization (CDMO) landscape with an emphasis on the key trends and growth opportunities across the global biologics outsourcing market. It also highlights the shifting focus and investments of pharma/biotech participants toward BioCDMOs for innovative biologics discovery, development, and manufacturing.

With the changing market landscape, BioCDMOs are shifting toward providing value-added services by establishing themselves as a one-stop-shop for their pharma clients. These companies are adopting advanced manufacturing technologies such as single-use/disposable bioreactors, continuous, POD manufacturing, and so on with the integration of IT-based solutions implementing the Industrial Internet of Things (IIoT) by means of strategic collaborations and partnerships. Larger participants are resorting to Mergers and Acquisitions (M&As) in order to gain specific therapeutic and technical expertise from smaller, niche BioCDMOs. While the US and Europe are key markets, the outsourcing trend is slowly shifting toward APAC with several new entrants providing cost-effective drug development services. Weniger anzeigen

Diagnostics has inarguably become an integral part of healthcare system, moving from reactionary science to predictive science; playing a vital role throughout the care continuum. While rising burden of chronic diseases, drug-resistant diseases and the increasing proportion of elderly population are the organic growth drivers, the shift towards creating individualized treatment plans and evolution of personalized drug discovery have been the largest inorganic growth contributors. Key service… Mehr anzeigen

Diagnostics has inarguably become an integral part of healthcare system, moving from reactionary science to predictive science; playing a vital role throughout the care continuum. While rising burden of chronic diseases, drug-resistant diseases and the increasing proportion of elderly population are the organic growth drivers, the shift towards creating individualized treatment plans and evolution of personalized drug discovery have been the largest inorganic growth contributors. Key service providers in this study are segmented into independent reference labs (IRLs), physician operated labs (POLs) and hospital labs. At the sub-segment level, this research study covers the shifting dynamics between these service providers including outsourcing and overall testing trends. The study also captures the additional play between the cash-strapped public and the technology-rich private sector.

While there has been exponential growth in demand for diagnostic services, there is a constant pressure to do so under budget and skill constraints. This has led to the rise of new technologies which are not only pushing the envelope on sensitive, rapid and accurate testing but are also affordable and bring down the cost of the total treatment cycle. This study identifies some of the key technology trends and growth opportunities, which are set to drive the market in the next five years.



Weniger anzeigen

The medical marijuana market is growing in the United States with the recent Food and Drug Administration (FDA) approval of Epidiolex (cannabidiol) oral solution for the treatment of seizures. Other marijuana-based products are under development for passing through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal level, marijuana is still considered an illegal Schedule 1 drug. Individual states, however, have laws in place for… Mehr anzeigen

The medical marijuana market is growing in the United States with the recent Food and Drug Administration (FDA) approval of Epidiolex (cannabidiol) oral solution for the treatment of seizures. Other marijuana-based products are under development for passing through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal level, marijuana is still considered an illegal Schedule 1 drug. Individual states, however, have laws in place for the legal use of medical marijuana, and in some states, for the use of recreational marijuana. Cannabidiol (CBD) products are also legally available in some US states as well as in many other countries. The market generates a lot of money, though much of that money is still considered a black market.

Many business segments are involved with the development of the medical marijuana market. Some businesses directly touch the plant product, such as growers, packers, transporters, and sellers. Other businesses operate in the medical marijuana industry but do not touch the plant product, including legal services, marketing and brand services, data and analytical services, insurance participants and hardware or software companies. The rules differ depending upon where a company stands related to the marijuana plant. This is a very different model than is in place for traditional pharmaceutical products.

The medical marijuana segment of the marijuana industry includes marijuana plant products, CBD products, and synthetically derived products targeting the cannabidiol receptors CB1 and CB2. There are several synthetic products currently on the markets in many countries other than the US. As a matter of fact, in Canada, not only is medical marijuana approved for use on the national level, its use is covered by Health Canada, the national government insurance plan. It is a growing market drawing keen interest from physicians, investors and regulators.


Weniger anzeigen

The rise in infectious diseases across Europe has led to a growing need for early detection and diagnosis of infectious diseases in the region. Point-of-care testing (POCT) is a vital part of the clinical diagnostics market and is rapidly evolving into the preferred testing mode as rapid infection diagnosis results in lower antibiotic intake, fewer lab tests for patients, and reduced treatment cost. This is cost-effective not just for patients but also for hospitals.

Obtaining the… Mehr anzeigen

The rise in infectious diseases across Europe has led to a growing need for early detection and diagnosis of infectious diseases in the region. Point-of-care testing (POCT) is a vital part of the clinical diagnostics market and is rapidly evolving into the preferred testing mode as rapid infection diagnosis results in lower antibiotic intake, fewer lab tests for patients, and reduced treatment cost. This is cost-effective not just for patients but also for hospitals.

Obtaining the result of a diagnostic test can take anything between a couple of hours to 3 days, depending on the disease. Rapid diagnosis is crucial for saving lives. New regulations, changing reimbursement laws, and technology advancements are all focusing on making tests accurate, operationally efficient, portable, and easy to use.

POCT is a segment that presents growth opportunities for a cross-section of players, ranging from OEMs to data integrators and technology vendors. The stakeholders need to be abreast of the challenges posed by the industry as well as anticipate new avenues of growth to innovate new business models and capitalize on the transformation that the market is undergoing. It is pertinent to understand key convergences that drive infectious disease POCT sector growth and the technological building blocks that contribute to the future functionality of this market. This study will enable vendors in this space to look at future opportunities in infectious disease POCT industry from application area and technology points of view and also at organic and inorganic means to monetize these opportunities. Weniger anzeigen

Shift Towards a 'Comprehensive Care Continuum' with the Adoption of Integrated Care Pathways that Combine Clinical Therapies with Wellness Programs

Globally, cardiometabolic diseases are witnessing a consistent rise in prevalence every year, with hypertension and diabetes among the leading conditions. A rising population of hypertension is, in turn, leading to growing incidence of chronic heart failure with about 26 million cases of CHF globally. Although drug therapies are the first… Mehr anzeigen

Shift Towards a 'Comprehensive Care Continuum' with the Adoption of Integrated Care Pathways that Combine Clinical Therapies with Wellness Programs

Globally, cardiometabolic diseases are witnessing a consistent rise in prevalence every year, with hypertension and diabetes among the leading conditions. A rising population of hypertension is, in turn, leading to growing incidence of chronic heart failure with about 26 million cases of CHF globally. Although drug therapies are the first line of treatment in cases of CHF, hypertension, and diabetes, obesity treatment requires a mixture of nutritional, behavioral, and drug therapies, wherein drugs act as an adjunct to the behavioral therapies.

With the growing number of cardiometabolic cases worldwide, the market is slowly shifting toward ‘Therapy-as-a-Service’ model, with the implementation of adjunct therapies such as digital therapeutics, AI-based predictive diagnostic tools as well as nutritional and behavioral therapies alongside traditional drug treatment. This has helped establish a comprehensive care continuum across the industry, with wellness programs playing an important role in disease diagnosis, treatment, and monitoring. Weniger anzeigen

Focus on Integrative Solutions Combining Dietary Supplements and Aesthetic Solutions with Clinical Therapeutics as the Market Moves Toward a ‘Prevent-Manage-Repair’ Continuum

The rapidly aging global population is placing immense pressure on healthcare systems across countries and regions. The improvement in life expectancy levels has created a large cohort of aged patients who suffer from one or more chronic diseases. Traditionally, the approach towards the management of this issue has… Mehr anzeigen

Focus on Integrative Solutions Combining Dietary Supplements and Aesthetic Solutions with Clinical Therapeutics as the Market Moves Toward a ‘Prevent-Manage-Repair’ Continuum

The rapidly aging global population is placing immense pressure on healthcare systems across countries and regions. The improvement in life expectancy levels has created a large cohort of aged patients who suffer from one or more chronic diseases. Traditionally, the approach towards the management of this issue has been on ‘repair’, i.e., treatment of the various age-related ailments such as Alzheimer's disease, Parkinson’s disease, osteoarthritis, osteoporosis, and age-related macular degeneration.

However, the industry is shifting focus and is widening its scope to a ‘prevent-manage-repair’ continuum, which is creating novel market opportunities for integrative approaches such innovative dietary supplements, aesthetics procedures, and alternative therapies (such as BHRT). Such approaches, along with advanced clinical therapeutics, such as regenerative medicine and pharmacological targeting of aging (focused on telomeres, rapalogs, senescent cell targeting, and mitochondria-based therapies) are key opportunities in this space.

Digital enablers are likely to gain prominence in the market, driving collaboration between drug and technology firms to cater to the ‘drug-as-a-service’ trend. Digital therapies that amalgamate mobile technology with AI and Big Data analytics for clinical effect will help lower costs and reduce drug side effects. Additionally, digital pills that can track medication consumption will improve drug adherence, a key challenge in the treatment of the elderly population. For example, the ABILIFY MYCITE from Proteus—a digital pill with an ingestible sensor, approved by the FDA for the delivery of Otsuka’s oral aripiprazole tablets—may boost adherence levels if used in the treatment of age-related disorders.

Weniger anzeigen

An overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies toward biologics development and manufacturing, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products.
The biologics manufacturing industry is presently in a growth stage owing to factors such… Mehr anzeigen

An overview of the global biologics development and manufacturing landscape with an emphasis on the seven leading CDMOs in the market. The study highlights the shifting focus and investments of bio-pharma companies toward biologics development and manufacturing, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products.
The biologics manufacturing industry is presently in a growth stage owing to factors such as complexity of molecules and complex manufacturing processes. This presents an immense potential for the market with pharmaceutical MNCs looking for outsourcing partners providing them with biologics development and manufacturing services at comparatively lower costs. The advent of personalized medicine calls for a shift toward flexible, small-volume manufacturing using single-use/ disposable bioreactors and using bio-analytical capabilities, thus exploring continuous processing technologies in modular facilities. Presently, the outsourcing of bio-analytical activities is comparatively lower across the industry, which provides ample opportunities to outsourcing partners in terms of services such as bio-analytical testing by means of building entrenched relationships with pharma MNCs. Further, bio-CDMOs are making use of advanced continuous manufacturing processes as opposed to the traditional batch processes, which reduces the time-to-market of the biologics and help the firms meet the growing demand. CDMOs are adopting several newer business models such as risk sharing models and value-based models to achieve a competitive edge in the ever-changing biologics manufacturing landscape. Using these approaches, there are also able to meet specific needs of their pharma partners in terms of drug development through out-licensing of the development and manufacturing expenses and acquiring flexible and modular manufacturing capabilities, thereby meeting the demand.
Weniger anzeigen

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from payers to providers have provided a strong impetus to the growth of the life sciences industry. The convergence of biopharmaceuticals, drug delivery… Mehr anzeigen

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from payers to providers have provided a strong impetus to the growth of the life sciences industry. The convergence of biopharmaceuticals, drug delivery devices, and companion diagnostics enabled by the digital connectivity is driving regulatory and commercial changes in many exciting ways for the industry. With the synergistic effect of advanced technologies, such as Artificial Intelligence, Big Data analytics, and cloud computing on the traditional life sciences industry, growth could be even faster in 2018. The paradox of the new growth rate is that its taking place even as the industry is grappling with the larger question – when will precision healthcare become a reality?

In this research deliverable, Frost & Sullivan’s senior analyst team provides bold perspectives and predictions for the global life sciences industry in 2018. The markets covered include pharmaceuticals and biotechnology, in vitro diagnostics, and research tools. The analysis captures the sectoral and regional trends and predictions that are expected to transpire over the upcoming year as organizations shift to prepare for the future. The key objective of this research service is to enable clients to identify growth opportunities and devise potential growth strategies in the transformational life sciences ecosystem. The report also provides a futuristic perspective on the competitive landscape, market, and technology trends. Weniger anzeigen

The healthcare market in India is evolving at a rapid pace. As per estimates, it is one of the fastest growing industries with an estimated compound annual growth rate (CAGR) of 23% from 2015 to 2020, and is expected to be a $280 billion market by 2021. Rising income levels, the growing geriatric population, greater penetration of healthcare in rural settings, and increasing health awareness with an emphasis on ‘preventative healthcare’, is expected to enhance the demand for healthcare services.

Across the world, women typically live longer than men. The reason behind the difference between male and female life expectancy is unclear but could be explained through biological, environmental, and behavioral factors. Because women typically outlive men, they are more likely to suffer from ill health and other age-related diseases. Women’s healthcare, especially in underdeveloped regions, remains largely confined to reproductive matters, particularly maternal health. Attention to other… Mehr anzeigen

Across the world, women typically live longer than men. The reason behind the difference between male and female life expectancy is unclear but could be explained through biological, environmental, and behavioral factors. Because women typically outlive men, they are more likely to suffer from ill health and other age-related diseases. Women’s healthcare, especially in underdeveloped regions, remains largely confined to reproductive matters, particularly maternal health. Attention to other significant women’s health issues, such as oncology, reproductive health, and urology, is growing rapidly.

Overall, advancements in women’s health diagnostic products are intense, and diagnostic technologies have been subjected to rapid change. Currently, women’s health diagnostic products are being targeted at markets outside of traditional hospitals or clinical laboratories. The demand for home healthcare services in women’s health is facing a steady increase; however, at the same time, there is pressure to lower costs and maintain the high quality of the care delivered at home. Continuous improvements in technology are bringing about a number of new diagnostic tests that consolidate high levels of accuracy with rapid, easy-to-use product designs.

This strategic research service provides key growth drivers and opportunities in clinical diagnostics and medical devices in the women's diagnostics market.
Weniger anzeigen

Prenatal genetic tests are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, 13 and carrier screens. They are gaining momentum in EU due to enhanced assay outcomes through non-invasive methodologies using next generation sequencing (NGS) techniques, increasing number of women choosing to undergo pregnancy at an advanced maternal age (over 35 years) and considerable popularity through social media and e-commerce channels. High level of merger and acquisition… Mehr anzeigen

Prenatal genetic tests are predominantly used to test disorders such as aneuploidies in chromosomes 21, 18, 13 and carrier screens. They are gaining momentum in EU due to enhanced assay outcomes through non-invasive methodologies using next generation sequencing (NGS) techniques, increasing number of women choosing to undergo pregnancy at an advanced maternal age (over 35 years) and considerable popularity through social media and e-commerce channels. High level of merger and acquisition activity apart from numerous collaborations with regional clinical labs has supported the participants in marketing their products across the European region. Moreover, companies are also exploring new avenues to market their product by strategically tying up with IVF clinics, physicians, genetic counsellors and OBGYNs. Partnership with big data companies is anticipated to be the next big leap in the prenatal genetic testing market, thereby providing interpretation of vast volumes of data to increase specificity, sensitivity, and cost of tests. The key business model emerging across the market is the collaboration of key participants with regional private clinical labs as well as public centres and organizations such as NHS to increase the market coverage in Europe.
The key objectives of this growth insights study are to track the transformations in the prenatal genetic test market landscape in Europe for 2016-2021. The study aims at identifying growth opportunities across the market and suggesting most profitable business models to market players. Furthermore, the study provides an in-depth revenue and market analysis of 4 key segments within the prenatal landscape: NIPT, carrier screening for cystic fibrosis, invasive tests, and miscarriage tests. The study highlights industry challenges, growth drivers, restraints, competitive developments, key mergers and acquisitions (M&As), and investment opportunities. Weniger anzeigen

Shortage of pathologists and the rise in new cancer cases are the key drivers for the adoption of digital pathology solutions globally. Digital pathology enhances the productivity of pathologists by 10% to 15%, thereby improving the overall efficiency of healthcare providers.

Digital pathology solutions find the best fit in oncology care. According to WHO estimates, the number of new cases is expected to rise by about 70% over the next two decades. Digital pathology solutions are likely… Mehr anzeigen

Shortage of pathologists and the rise in new cancer cases are the key drivers for the adoption of digital pathology solutions globally. Digital pathology enhances the productivity of pathologists by 10% to 15%, thereby improving the overall efficiency of healthcare providers.

Digital pathology solutions find the best fit in oncology care. According to WHO estimates, the number of new cases is expected to rise by about 70% over the next two decades. Digital pathology solutions are likely to be useful in cancer diagnosis, as these systems allow physicians to take and consider the second opinion on critical cases quickly. In addition, use of digital pathology in drug discovery enables pharmaceutical companies to remove bias and provide quantifiable results.

The US research segment currently contributes to a significant part of the revenue, as digital pathology devices were not approved for primary diagnosis until Philips got the approval for Intellisite in April 2017. The approval is expected to increase the adoption of digital pathology in primary diagnosis, and further approvals of whole slide scanners are expected in the next 3 to 5 years, leading to an increase in competition.

Despite higher efficiency and clinical effectiveness, the high cost of digital pathology solutions has been one of the key market growth restraints, especially in the small-to-mid-sized laboratory segment. However, this is expected to change in the future, driven by new business models and partnerships among vendors.

The research service provides an overview of the global digital pathology system market and provides a five-year forecast from 2016 to 2021. Weniger anzeigen

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. Across therapy areas, oncology and… Mehr anzeigen

This study on the "Global Biologics Market: Companies-to-Action" presents an overview of the global biologics landscape with an emphasis on the top 10 leading bio-pharma companies in the market. The study highlights the shifting focus and investments of bio-pharma companies towards biologics discovery and development, which is attributed to the growing demand for innovative therapies as well as the loss of patent exclusivity of the leading pharma products. Across therapy areas, oncology and diabetes emerge as the key contributing segments alongside immunology and cardiovascular diseases. Several small- to mid-sized companies are increasingly focusing on oncology and immunology segments which have high unmet needs and higher acceptability for innovative therapies. Furthermore, across the biologics sub-segments, monoclonal antibodies (mAb) and bioengineered vaccines are amongst the highest contributing segments, with most companies having a strong focus on developing a mAb pipeline. On the other hand, cell and gene therapy are expected to show a strong potential, especially across the rare diseases market, with leading companies like Amgen, Sanofi, Pfizer, etc., investing in molecules in the early stages of clinical development. These molecules, if approved, have the potential of becoming key blockbuster products, propelling the market by more than 20% in the next few years. To achieve expertise across specific therapy areas and biologic sub-segments, bio-pharma companies collaborate with Contract Development and Manufacturing Organizations (CDMOs), Contract Research Organizations (CROs), and digital and medical equipment companies that provide access to innovative proprietary technologies for research and development activities and to optimize the manufacturing process of complex biologics. Alongside industry and academic research collaborations, companies are also focusing on partnering with IT players such as IBM Watson, Intel etc.. Weniger anzeigen

The Western European Oncology Diagnostics Market, Forecast to 2021 study presents an overview of the oncology diagnostics market landscape in the Western European countries, with a focus on EU 5. The analysis provides forecasts for the EU 5 markets, segmented by types of cancer, which include breast cancer, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, and lung cancer.

The oncology diagnostics market is experiencing consolidation between the major pharma and… Mehr anzeigen

The Western European Oncology Diagnostics Market, Forecast to 2021 study presents an overview of the oncology diagnostics market landscape in the Western European countries, with a focus on EU 5. The analysis provides forecasts for the EU 5 markets, segmented by types of cancer, which include breast cancer, ovarian cancer, cervical cancer, prostate cancer, colorectal cancer, and lung cancer.

The oncology diagnostics market is experiencing consolidation between the major pharma and diagnostic participants who are collaborating to devise and implement disruptive technologies for cancer diagnosis. The research focuses on highlighting some of the major trends occurring in the market alongside these strategic partnerships. Furthermore, emphasis is on the key challenges in the European market in terms of regulations pertaining to companion diagnostics for cancer detection and monitoring. The deliverable outlines some of the major drivers and restraints, impact analysis of major growth opportunities, as well as market engineering measurements.

With early detection being a key imperative in oncology diagnosis, the study highlights some of the major technology trends in the market with the application of Artificial Intelligence and Big Data as well as Liquid Biopsy and Next Generation Sequencing, which are expected to reduce the turnaround time for cancer detection, thus speeding up the treatment uptake. Emphasis is given to the emerging biomarkers across the types of cancer, which are expected to aid in faster and easier diagnosis of the disease. Furthermore, analysis is provided for the key participants that are working towards devising new solutions which help to detect these biomarkers, thereby supporting accurate detection and monitoring. In addition to the key participants across the market, new market entrants by different cancer types have been profiled.
Weniger anzeigen

Despite global economic and industry challenges, in-vitro diagnostics (IVD) markets continue to grow, mainly due to fast-growing segments like molecular diagnostics, point-of-care testing (POCT), and tissue diagnostics.. A few market dynamics are either positively or negatively affecting certain specific segments in the IVD space; for example, the self-monitoring blood glucose (SMBG) segment's growth in emerging markets is severely dampened by the slowing growth from reimbursement reductions in… Mehr anzeigen

Despite global economic and industry challenges, in-vitro diagnostics (IVD) markets continue to grow, mainly due to fast-growing segments like molecular diagnostics, point-of-care testing (POCT), and tissue diagnostics.. A few market dynamics are either positively or negatively affecting certain specific segments in the IVD space; for example, the self-monitoring blood glucose (SMBG) segment's growth in emerging markets is severely dampened by the slowing growth from reimbursement reductions in Western Europe.The broad applicability of POCT, combined with downward pricing trends enabled by microfluidics integration, supports the long-term growth of this segment. The Western European markets continue to drive molecular diagnostics segment growth rather than the emerging Eastern European markets.

The recent success of companion diagnostic tests and personalised medicine is driving the uptake of various tests in an aim to save costs, thus opening up an opportunity to expand the test menus in existing installs. Diagnostic testing will continue to move towards process simplicity and decentralisation. IVD market participants are expected to employ a diverse set of strategies rather than rely on comprehensive product portfolios to grow their businesses. Companies are also gaining new market access through acquisitions, and this has intensified competition among tier 1 participants.

This study offers comprehensive information on every aspect of the IVD market. It is segmented into 8 subdivisions, namely, immunochemistry, POCT, SMBG, molecular diagnostics, clinical microbiology, haemostasis, hematology, and tissue diagnostics. Discussion on key trends and opportunities and company profile analysis by segment are also provided. In addition, there are dedicated country chapters for the key Western European markets (Germany, France, the United Kingdom, Spain, Italy, Benelux, and Scandinavia) and a snapshot of the regulatory policies awaiting to transform the industry. Weniger anzeigen

The cost of genomic sequencing has significantly declined in the recent past with the utilization of high-throughput sequencers creating opportunities for Next-generation Sequencing (NGS) informatics to develop genetic insights from the growing volume of sequencing data. As NGS technologies mature and the market stakeholders develop clarity on industry requirements, the market is expected to undergo significant transformation. Primary and secondary analyses are getting automated and… Mehr anzeigen

The cost of genomic sequencing has significantly declined in the recent past with the utilization of high-throughput sequencers creating opportunities for Next-generation Sequencing (NGS) informatics to develop genetic insights from the growing volume of sequencing data. As NGS technologies mature and the market stakeholders develop clarity on industry requirements, the market is expected to undergo significant transformation. Primary and secondary analyses are getting automated and commoditized with market growth being propelled by clinically focused tertiary analysis solutions. Support from government and R&D labs, launch of national-level genomic data collection initiatives, and expanding usage in the clinical space have provided impetus to the market in Europe.

The NGS Informatics market has been segmented into 3 segments: secondary analysis, tertiary analysis and data storage. The European NGS Informatics market was worth $236.6 million in 2016 and is expected to reach $508.6 million by 2021 at a CAGR of 16.5%. The European NGS informatics is a competitive space with a handful global players and a large number of regional players vying for market share.

Europe is a key market in the global NGS informatics space with the presence of cutting-edge NGS technology infrastructure, a highly educated population receptive of NGS technologies and significant government support. UK, Germany, and France are likely to emerge as key markets. However, with a fragmented market and diverse regulatory and reimbursement rules across nations, NGS informatics companies are likely to face challenges in successful commercialization of their solutions.
Weniger anzeigen

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments… Mehr anzeigen

Patent expiration and increased use of traditional generic drugs are leading to a shift of focus in the pharmaceutical industry toward investment in specialty drugs and high growth areas such as biosimilars. Expensive biopharmaceuticals are largely used for life-saving disorders such as cancer and diabetes, the incidence of which is increasing with population aging in Europe. Moreover, patent expiry of key product classes and a growing emphasis on cost effectiveness are making governments switch to affordable alternatives. There is thus a tremendous opportunity for biosimilar manufacturers. However, the development of biosimilar drugs is riddled with complexities, from R&D to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry.

About 30 companies are actively developing biosimilar medicines and are researching on the biosimilar versions of 16 distinct molecules that will lead to greater competition by 2020, with 8 major biologic medicines expected to lose exclusivity by 2020.

The next five years are going to be an interesting period in the biosimilars market as a number of biologic drugs are going to lose their exclusivity. On the one hand, this will significantly reduce costs for patients and health systems, on the other, it will pose challenges for regulators to confirm the similarity of the biosimilar to the original biologic in terms of efficacy and safety. The experience of European healthcare companies has been encouraging in the 10 years since the endorsement of the first biosimilar in the EU.

Pricing and physician awareness and support from the regulatory agencies are expected to be key factors driving success in the biosimilars market. Europe is expected to remain the largest contributor to biosimilars revenue worldwide for the next 5–7 years.
Weniger anzeigen

Role of Pharma in Indian Biotech Industry- Global Pharma Offering Growth Opportunity Worth ~$400 billion by 2020

This research service on the global pharma extractables and leachables (E&L) testing market addresses the market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year for the deliverable is 2015 while forecasts have been provided from 2016 to 2020.

The pharma E&L testing market is expected to expand at a compound annual growth rate of 12.1% from 2015 to 2020, driven by the increasing adoption of single use technologies… Mehr anzeigen

This research service on the global pharma extractables and leachables (E&L) testing market addresses the market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year for the deliverable is 2015 while forecasts have been provided from 2016 to 2020.

The pharma E&L testing market is expected to expand at a compound annual growth rate of 12.1% from 2015 to 2020, driven by the increasing adoption of single use technologies, increased demand due to stringent regulatory scrutiny, CROs evolving as development partners and increasing prominence of biologics leading to need for comprehensive E&L testing programs. With the increasing prominence of single use systems (SUS), the global E&L testing market is expected to experience a robust growth. Emerging markets such as India and China are becoming hubs for contract manufacturing for such services, as these countries are building strong local expertise in analytical laboratory testing.

The pharma industry is becoming more aware of the impact of E&L for protection of patients, leading to increased and stringent scrutiny by regulatory agencies. Bio/Pharma companies are increasingly outsourcing these services to reduce the burden on internal staff and also expedite the time to market for drugs. Weniger anzeigen

Disruptive technologies in NGS are revolutionising the healthcare industry. Launch of high-throughput sequencers has set new service standards, with focus on superior coverage and accuracy. Low-cost and quick turnaround features have amplified NGS uptake as an alternative to traditional methods such as microarray, capillary electrophoresis, and Sanger, propelling the demand for NGS services across areas such as human genetics, plant and animal biotech, agriculture, food and drug safety, and… Mehr anzeigen

Disruptive technologies in NGS are revolutionising the healthcare industry. Launch of high-throughput sequencers has set new service standards, with focus on superior coverage and accuracy. Low-cost and quick turnaround features have amplified NGS uptake as an alternative to traditional methods such as microarray, capillary electrophoresis, and Sanger, propelling the demand for NGS services across areas such as human genetics, plant and animal biotech, agriculture, food and drug safety, and forensics.

The European NGS services market is forecast to grow at a CAGR of 15.4% from 2016 to 2023 to reach $605.0 million by 2023. A relatively slow adopter of the technology, Europe now contributes to roughly a third of the global NGS services market size. Government-backed large-scale projects in the region such as the 100,000 Genomes Project of the United Kingdom (UK) and France Genomic Medicine Plan 2025 are poised to bring NGS to the forefront. Industry stakeholders are adapting to current market needs and aligning services with growth opportunities in research and clinical applications.

The research service explores current industry trends and market response to the growing sequencing demand. The NGS services market in Europe has been comprehensively studied to understand the core value proposition of game-changing service providers. Industry-wide collaborations, focusing on diversified applications and value-added services, have also been discussed.

The study provides an overview of the regional market dynamics focusing on key disruptive factors affecting market growth. The regional market is further segmented and market attractiveness of top countries has been studied. Market size estimations have been provided for Germany, United Kingdom, France, Spain, Italy, and Rest of Europe. Detailed coverage of NGS services market in Germany, UK, and France has been included. Weniger anzeigen

This market insight on the global cell banking market analyses disruptive technologies and provides details on game-changing companies. Biopharmaceutical companies are increasingly partnering with CMOs and CROs to store their proprietary cell lines and develop new ones. With increased collaborations, CMOs are coming up with niche and specific services for cell line development and cell banking. They are focusing on providing gene to GMP services, thereby expanding their service portfolios… Mehr anzeigen

This market insight on the global cell banking market analyses disruptive technologies and provides details on game-changing companies. Biopharmaceutical companies are increasingly partnering with CMOs and CROs to store their proprietary cell lines and develop new ones. With increased collaborations, CMOs are coming up with niche and specific services for cell line development and cell banking. They are focusing on providing gene to GMP services, thereby expanding their service portfolios. Mammalian cell culture technology is the highest-growing system across all other cell systems. With the increase in infectious diseases, the development of novel mammalian cell culture systems is expected to evolve. With the growing need for the proper storage of cultured cell banks, CMOs are developing long-term preservation techniques through continuous temperature monitoring. With the emergence of single-use technologies and new developments in cryopreservation technologies and upstream/downstream processes, the cell banking market is expected to experience robust growth, with the major share being captured by contractors as they specialise in new technologies. CMOs are turning towards emerging markets such as Asia-Pacific. However, issues with delivery, service, IP protection, and regulatory and product quality are curbing growth. The key companies covered in the study include SGS Life Sciences, Charles River Laboratories, Wuxi AppTech, BioReliance Corporation, Eurofins, and Lonza. Weniger anzeigen

Strong Focus on Digital Footprint and Beyond-the-pill Services Propel Companies to Innovate and Stay on the Growth Trajectory

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing European pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key… Mehr anzeigen

Strong Focus on Digital Footprint and Beyond-the-pill Services Propel Companies to Innovate and Stay on the Growth Trajectory

Frost & Sullivan has recently completed a comprehensive analysis on the current and future strategic imperatives of game-changing European pharmaceutical companies. The analysis primarily focuses on the changing trends in the pharmaceutical industry with respect to drug research and development, manufacturing, supply chain, and marketing. The study provides key insights on the transforming pharmaceutical value chain, with the adoption of technology and shift towards digitalisation of key processes across drug development and manufacturing. It analyzes the dynamics catalyzing growth, profiles organizations presenting significant growth opportunities, and outlines innovative industry trends of key participants who play a vital role in the pharmaceutical landscape.

The research covers the top 5 European pharmaceutical companies, based on their industry position. The companies included in the study are Bayer, AstraZeneca, Roche, Novartis, and Sanofi. These companies are benchmarked across 5 key growth levers, namely core areas of focus, digital footprint, value chain excellence, strategic collaborations and partnerships, and beyond-the-pill services and solutions.

Highlights of the company profiles include:
• Company snapshot
• Performance analysis (market revenue forecast)
• Portfolio analysis
• Key marketed products and patent expiry
• SWOT analysis
• Strategic analysis of growth levers Weniger anzeigen

This research service on the global pharmaceutical stability testing market addresses market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year is 2015 and forecasts are provided from 2016 to 2020.

The market is expected to grow at a CAGR of 9.4% till 2020, driven by an explosion of new approval applications, consolidation, and globalization of both small and large molecule industries. Also, with the continuous growth… Mehr anzeigen

This research service on the global pharmaceutical stability testing market addresses market sizing, emerging trends, and technologies, and provides a snapshot of the key participants in the market. The base year is 2015 and forecasts are provided from 2016 to 2020.

The market is expected to grow at a CAGR of 9.4% till 2020, driven by an explosion of new approval applications, consolidation, and globalization of both small and large molecule industries. Also, with the continuous growth of biologics, the global pharmaceutical stability testing market is expected to witness robust growth. Biologics stability testing, being more complicated than that of small molecules, is expected to contribute significantly to overall revenue. Biopharmaceutical companies are consolidating stability storage and limiting testing to one facility whereas pharmaceutical companies are moving toward decentralized stability testing, and centralized management and reporting. These companies are opting for single stability storage deals and building strategic relationships with CROs. Also, they are looking for end-to-end services to outsource the entire development project to a single CRO.

Early-stage biotech is identified as the largest growth segment for stability services, and has posted the highest increase during the past few years. For new-generation therapies and new trends in formulations such as non-aqueous and liposomal, many original study strategies apply but new strategies need to be adopted to deal with some of the nuances. Asia-Pacific, especially India and China, is emerging as a big growth opportunity area for this market. Several large CROs are exploring acquisitions here. Many local participants in these markets provide specialized services for global participants. There is also high demand for stability testing for such products in the local markets. Weniger anzeigen

This research service on the global cell banking market addresses market sizing, emerging trends, and technologies and provides a snapshot of the key participants in the market. The base year considered is 2015 and forecasts are provided from 2016 to 2020.

The cell banking market is expected to grow at a CAGR of 16.7% till 2020, driven by specialized and technologically advanced services offered by CROs/CMOs, growing demand for gene and cell therapy, and increased partnerships with… Mehr anzeigen

This research service on the global cell banking market addresses market sizing, emerging trends, and technologies and provides a snapshot of the key participants in the market. The base year considered is 2015 and forecasts are provided from 2016 to 2020.

The cell banking market is expected to grow at a CAGR of 16.7% till 2020, driven by specialized and technologically advanced services offered by CROs/CMOs, growing demand for gene and cell therapy, and increased partnerships with biopharmaceutical companies. Also, there are an increasing number of grants, incentives, and private investments in research on cell therapeutics and biopharmaceuticals. Master cell banking and storage accounted for the largest shares of cell banking revenue, among the different bank types, and the different phases of cell banking, respectively, in 2015.

The study also provides market forecasts for cell line development, a preliminary step to cell banking. Cell line development is driven by technological advancements and increasing demand for cancer therapeutics and monoclonal antibodies. Mammalian cell lines are the most used source for cell line development in all regions. The United States leads in cell line development and cell banking, closely followed by Europe and Asia-Pacific. The fastest growth rate was experienced in Asia-Pacific, with the hotbeds in India and China. Due to increasing demand for cell lines and cell banking, CMOs/CROs are focusing on providing end-to-end services by expanding their service portfolio and collaborating with biopharmaceutical companies. Weniger anzeigen

Emerging Business Models Drive Transformation

The Global Contract Manufacturing Organization Market is undergoing a transformation propelled by the evolving pharmaceutical ecosystem. Changing trends such as implementation of differentiating business models like the emergence of virtual biotech, out-licensing and risk sharing between pharma and CMOs, pattern shift from cost control to value added services, new innovative technical capabilities in niche HPAPIs etc. are having a… Mehr anzeigen

Emerging Business Models Drive Transformation

The Global Contract Manufacturing Organization Market is undergoing a transformation propelled by the evolving pharmaceutical ecosystem. Changing trends such as implementation of differentiating business models like the emergence of virtual biotech, out-licensing and risk sharing between pharma and CMOs, pattern shift from cost control to value added services, new innovative technical capabilities in niche HPAPIs etc. are having a significant impact on this market. Several CMOs are transforming themselves from low margin to high margin formulation manufacturers in order to beat the competition, propelled by the growth in outsourced biopharma manufacturing and expanding services into the early-stage of drugs.

Frost & Sullivan has recently completed a comprehensive Analysis of the Global Contract Manufacturing Organization (CMO) Market. The key objectives of this research service are to gain an in-depth knowledge of the major market segments (Active Pharmaceutical Ingredients, Solid, Liquid and Semi-solid, Injectable Dose Formulations) and understand the value chain from clinical to commercial and drug substrate to final drug product of the CMOs, biotech & pharma companies. We aim to analyze the dynamics catalyzing growth, profile organizations presenting significant growth opportunities and to outline the industry consolidation trends which will continue shaping the future of contract outsourcing.

Through our research, we were able to analyze capacity & utilization to understand supply-demand conditions and forecast future revenues for the contract manufacturing market, both globally and regionally for developed as well as emerging economies. It would enable the market participants to take strategic decisions and enable CMOs to position their assets with pharma companies in order to stay ahead of their competitors and gain significant share in the market.

Weniger anzeigen

In a qualitative study, medical-surgical and intensive care staff nurses reported that they did not complete a significant amount of nursing care on regular basis. Thus, it was determined that a quantitative tool was needed to measure the amount and type of missed nursing care and the reasons for missing care.
The authors report the results of a psychometric evaluation of this tool (The Missed Nursing Care Survey [MISSCARE Survey]) to measure missed nursing care (part A) and the reasons for… Mehr anzeigen

In a qualitative study, medical-surgical and intensive care staff nurses reported that they did not complete a significant amount of nursing care on regular basis. Thus, it was determined that a quantitative tool was needed to measure the amount and type of missed nursing care and the reasons for missing care.
The authors report the results of a psychometric evaluation of this tool (The Missed Nursing Care Survey [MISSCARE Survey]) to measure missed nursing care (part A) and the reasons for missed nursing care (part B).

Weniger anzeigen